A 2011 study of combined kidney and donor-cell transplantation in cynomolgus monkeys (Nadazdin et al., Sci Transl Med 2011) established that recipients with high pretransplant donor-reactive frequencies among memory T cells (TMEMs) — above 1000 IFN-γ-producing cells per 10^6 sorted TMEMs by ELISPOT — acutely reject under nonmyeloablative mixed-chimerism conditioning, while recipients with low frequencies (below 250 per 10^6 TMEMs) become tolerant, leaving open whether the donor-reactive TMEMs expanding in rejecting recipients directly eliminate donor hematopoiesis, which tolerogenic mechanisms operate, and whether memory-targeted interventions can extend tolerance induction. Later work substantially resolved the mechanism question in tolerant recipients — donor-reactive clonal deletion together with early expansion of induced donor-specific regulatory T cells — and provided proof of concept that depleting CD2-high CD8+ effector-memory cells (alefacept) or CD8+ memory cells permits chimerism and tolerance in delayed protocols. What remains open is the causal and translational core: whether donor-reactive TMEMs are necessary and/or sufficient for elimination of donor hematopoietic cells and chimerism loss as opposed to memory-independent mechanisms; whether the pretransplant donor-reactive TMEM frequency thresholds generalize as quantitative predictors in larger primate cohorts and in human mixed-chimerism protocols; and whether memory-targeted conditioning can safely permit tolerance induction across a broader range of preexisting memory burdens.

Background

Transplantation tolerance — indefinite acceptance of an organ allograft without maintenance immunosuppression — is routinely achieved in laboratory mice but has been difficult to reproduce in humans and nonhuman primates. The most reproducible primate strategy is mixed hematopoietic chimerism: the recipient receives nonmyeloablative conditioning (low-dose total body irradiation, local thymic irradiation, and T-cell-depleting anti-thymocyte globulin), donor bone marrow is infused together with the kidney allograft, and only a short course of a calcineurin inhibitor such as cyclosporine A follows. Donor and host hematopoietic cells then coexist transiently in the blood (mixed chimerism), and in a fraction of recipients the graft survives long-term after all drugs are stopped.

A leading explanation for the mouse-to-primate gap is alloreactive memory T cells. Laboratory mice are immunologically naive, whereas primates accumulate memory T cells through infections, pregnancies, transfusions, and environmental antigen exposure; some of these memory cells cross-react with allogeneic MHC molecules of an unrelated donor, a phenomenon called heterologous immunity. Such memory cells activate faster than naive cells, require less costimulation, and resist both conventional immunosuppression and costimulation blockade. In the source study, TMEMs were isolated from peripheral blood by fluorescence-activated cell sorting using the CD95 and CD28 surface markers, and donor reactivity was quantified by ELISPOT (an assay that counts individual cytokine-secreting cells) as the number of donor-stimulated cells producing interferon-gamma (IFN-γ) per 10^6 sorted TMEMs. Among eight cynomolgus recipients of combined kidney and donor-cell transplantation (donor bone marrow in six, donor spleen cells in two, including one of the intermediate-frequency animals), the three with pretransplant donor-reactive frequencies below 250 per 10^6 TMEMs became tolerant (graft survival beyond 250 days without chronic rejection), the three above 1000 per 10^6 TMEMs acutely rejected within 60 to 90 days, and two animals with intermediate frequencies had variable outcomes, implying additional modulating factors. After conditioning, total TMEM numbers expanded homeostatically in both groups (lymphopenia-driven proliferation of residual memory-phenotype cells), but only the rejecting animals showed expansion and activation of donor-specific TMEMs.

The study left several issues unresolved: whether the expanding donor-reactive TMEMs are directly responsible for eliminating donor hematopoietic cells, given that chimerism is lost in many animals and even tolerant recipients lose chimerism without detectable anti-donor T-cell reactivity; which mechanisms maintain tolerance in the successful recipients — antigen-specific clonal deletion versus active regulation by regulatory T cells (Tregs, suppressive CD4+FOXP3+ cells); whether depleting or functionally blocking alloreactive TMEMs before conditioning could reproducibly permit tolerance induction across preexisting memory burdens; and whether the empirical frequency thresholds generalize to larger cohorts and to humans. The mechanism component has since been largely settled: in tolerant monkeys, donor-specific CD8 T-cell responses are lost while donor-reactive CD4+FOXP3+ induced Tregs expand, and in tolerant human combined kidney/bone-marrow recipients, high-throughput T-cell-receptor sequencing shows deletion of donor-reactive clones alongside early enrichment and expansion of donor-specific Tregs. On the interventional side, proof-of-concept studies showed that depleting memory-cell subsets can permit chimerism and tolerance induction in delayed protocols: alefacept, an LFA-3-Ig fusion protein targeting the T-cell surface receptor CD2, preferentially removes CD2-high effector-memory cells and achieved immunosuppression-free renal allograft survival in monkeys, though without stratifying recipients by pretransplant donor-reactive frequency. The unresolved question is the causal and translational core stated below: does the preexisting donor-reactive memory compartment directly eliminate donor hematopoiesis, can its pretransplant frequency serve as a validated predictive threshold, and can it be safely targeted to widen the window for tolerance induction.

Problem Statement

Determine, in primate mixed-chimerism kidney transplantation, whether preexisting donor-reactive memory T cells are causally responsible for eliminating donor hematopoietic cells — that is, for the loss of mixed chimerism and the associated failure of tolerance induction — or whether donor hematopoiesis is lost through memory-independent mechanisms, and identify those mechanisms. Concretely: (i) establish the necessity and/or sufficiency of donor-reactive TMEMs for loss of donor hematopoietic chimerism through donor-specific manipulation (selective depletion, antigen-specific functional blockade, or adoptive transfer of sorted donor-reactive TMEMs) with lineage-resolved chimerism monitoring, distinguishing TMEM-mediated elimination from homeostatic proliferation, NK-cell-mediated rejection, and antibody-mediated elimination of donor hematopoiesis; (ii) determine whether the pretransplant donor-reactive TMEM frequency thresholds observed in the original eight-monkey cohort — tolerance below roughly 250 and acute rejection above roughly 1000 IFN-γ-producing cells per 10^6 TMEMs — generalize as quantitative predictors in larger nonhuman-primate cohorts and in human mixed-chimerism protocols, including the prevalence and predictive value of pretransplant memory alloreactivity in transplant candidates; and (iii) determine whether interventions that selectively deplete or functionally block alloreactive TMEMs (for example CD2-directed depletion of CD2-high effector-memory cells) can safely and reproducibly permit tolerance induction across a broader range of preexisting memory burdens, and which additional cellular or humoral factors govern the variable outcomes of recipients with intermediate pretransplant donor-reactive frequencies. The mandatory core of this problem is (i), the causal necessity-and-sufficiency determination, which is to be resolved from the available primate evidence; parts (ii) and (iii) are extensions to be addressed only to the extent that existing cohorts, trials, and published data permit, so that resolving (i) constitutes a complete answer to the central question while (ii) and (iii) are reported as far as the evidence allows. The tolerogenic mechanisms operating in successfully tolerized recipients (clonal deletion plus regulatory T cells) are considered established background and are not part of the open question.

References

  1. Nadazdin O, Boskovic S, Murakami T, Tocco G, Smith RN, Colvin RB, Sachs DH, Allan J, Madsen JC, Kawai T, Cosimi AB, Benichou G. Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Science Translational Medicine 2011;3(86):86ra51. DOI: 10.1126/scitranslmed.3002093. https://doi.org/10.1126/scitranslmed.3002093
  2. Setoguchi K, Kishimoto H, Kobayashi S, Shimmura H, Ishida H, Toki D, Suzuki T, Ohnuki K, Tate Y, Fujioka S, Abe R, Tanabe K. Potential role of host effector memory CD8+ T cells in marrow rejection after mixed chimerism induction in cynomolgus monkeys. Transplant Immunology 2010;23(4):194-203. DOI: 10.1016/j.trim.2010.06.010. https://doi.org/10.1016/j.trim.2010.06.010
  3. Yamada Y, Boskovic S, Aoyama A, Murakami T, Putheti P, Smith RN, Ochiai T, Nadazdin O, Koyama I, Boenisch O, Najafian N, Bhasin MK, Colvin RB, Madsen JC, Strom TB, Sachs DH, Benichou G, Cosimi AB, Kawai T. Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. American Journal of Transplantation 2012;12(2):330-340. DOI: 10.1111/j.1600-6143.2011.03795.x. https://doi.org/10.1111/j.1600-6143.2011.03795.x
  4. Lee S, Yamada Y, Tonsho M, Boskovic S, Nadazdin O, Schoenfeld D, Cappetta K, Atif M, Smith RN, Cosimi AB, Benichou G, Kawai T. Alefacept promotes immunosuppression-free renal allograft survival in nonhuman primates via depletion of recipient memory T cells. American Journal of Transplantation 2013;13(12):3223-3229. DOI: 10.1111/ajt.12500. https://doi.org/10.1111/ajt.12500
  5. Kawai T, Sachs DH, Sprangers B, Spitzer TR, Saidman SL, Zorn E, Tolkoff-Rubin N, Preffer F, Crisalli K, Gao B, Wong W, Morris H, LoCascio SA, Sayre P, Shonts B, Williams WW, Smith RN, Colvin RB, Sykes M, Cosimi AB. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. American Journal of Transplantation 2014;14(7):1599-1611. DOI: 10.1111/ajt.12731. https://doi.org/10.1111/ajt.12731
  6. Morris H, DeWolf S, Robins H, Sprangers B, LoCascio SA, Shonts BA, Kawai T, Wong W, Yang S, Zuber J, Shen Y, Sykes M. Tracking donor-reactive T cells: evidence for clonal deletion in tolerant kidney transplant patients. Science Translational Medicine 2015;7(272):272ra10. DOI: 10.1126/scitranslmed.3010760. https://doi.org/10.1126/scitranslmed.3010760
  7. Yamada Y, Nadazdin O, Boskovic S, Lee S, Zorn E, Smith RN, Colvin RB, Madsen JC, Cosimi AB, Kawai T, Benichou G. Repeated injections of IL-2 break renal allograft tolerance induced via mixed hematopoietic chimerism in monkeys. American Journal of Transplantation 2015;15(12):3055-3066. DOI: 10.1111/ajt.13382. https://doi.org/10.1111/ajt.13382
  8. Hotta K, Aoyama A, Oura T, Yamada Y, Tonsho M, Huh KH, Kawai K, Schoenfeld D, Allan JS, Madsen JC, Benichou G, Smith RN, Colvin RB, Sachs DH, Cosimi AB, Kawai T. Induced regulatory T cells in allograft tolerance via transient mixed chimerism. JCI Insight 2016;1(10):e86419. DOI: 10.1172/jci.insight.86419. https://doi.org/10.1172/jci.insight.86419
  9. Benichou G, Gonzalez B, Marino J, Ayasoufi K, Valujskikh A. Role of memory T cells in allograft rejection and tolerance. Frontiers in Immunology 2017;8:170. DOI: 10.3389/fimmu.2017.00170. https://doi.org/10.3389/fimmu.2017.00170
  10. Zuber J, Sykes M. Mechanisms of mixed chimerism-based transplant tolerance. Trends in Immunology 2017;38(11):829-843. DOI: 10.1016/j.it.2017.07.008. https://doi.org/10.1016/j.it.2017.07.008
  11. Sprangers B, DeWolf S, Savage TM, Morokata T, Obradovic A, LoCascio SA, Shonts B, Zuber J, Lau SP, Shah R, Morris H, Steshenko V, Zorn E, Preffer FI, Olek S, Dombkowski DM, Turka LA, Colvin R, Winchester R, Kawai T, Sykes M. Origin of enriched regulatory T cells in patients receiving combined kidney-bone marrow transplantation to induce transplantation tolerance. American Journal of Transplantation 2017;17(8):2020-2032. DOI: 10.1111/ajt.14251. https://doi.org/10.1111/ajt.14251
  12. Savage TM, Shonts BA, Obradovic A, Dewolf S, Lau S, Zuber J, Simpson MT, Berglund E, Fu J, Yang S, Ho SH, Tang Q, Turka LA, Shen Y, Sykes M. Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 2018;3(22):e124086. DOI: 10.1172/jci.insight.124086. https://doi.org/10.1172/jci.insight.124086
  13. Hotta K, Oura T, Dehnadi A, Boskovic S, Matsunami M, Rosales I, Smith RN, Colvin RB, Cosimi AB, Kawai T. Long-term nonhuman primate renal allograft survival without ongoing immunosuppression in recipients of delayed donor bone marrow transplantation. Transplantation 2018;102(4):e128-e136. DOI: 10.1097/TP.0000000000002078. https://doi.org/10.1097/TP.0000000000002078
  14. Montero N, Farouk S, Gandolfini I, Crespo E, Jarque M, Meneghini M, Torija A, Maggiore U, Cravedi P, Bestard O. Pretransplant donor-specific IFNγ ELISPOT as a predictor of graft rejection: a diagnostic test accuracy meta-analysis. Transplantation Direct 2019;5(5):e451. DOI: 10.1097/TXD.0000000000000886. https://doi.org/10.1097/TXD.0000000000000886
  15. Oura T, Hotta K, Rosales I, Dehnadi A, Kawai K, Lee H, Benedict Cosimi A, Kawai T. Addition of anti-CD40 monoclonal antibody to nonmyeloablative conditioning with belatacept abrogated allograft tolerance despite induction of mixed chimerism. Transplantation 2019;103(1):168-176. DOI: 10.1097/TP.0000000000002417. https://doi.org/10.1097/TP.0000000000002417
  16. Thaiss CC, Oura T, Sasaki H, Dehnadi A, Matsunami M, Rosales IA, Cosimi AB, Kawai T. Importance of hematopoietic mixed chimerism for induction of renal allograft tolerance in nonhuman primates. Transplantation 2019;103(4):689-697. DOI: 10.1097/TP.0000000000002470. https://doi.org/10.1097/TP.0000000000002470
  17. Lee KW, Park JB, Park H, Kwon Y, Lee JS, Kim KS, Chung YJ, Rhu JS, Choi S, Kwon GY, Kim HJ, Kang ES, Jung CW, Shin EC, Kawai T, Kim SJ, Joh JW. Inducing transient mixed chimerism for allograft survival without maintenance immunosuppression with combined kidney and bone marrow transplantation: protocol optimization. Transplantation 2020;104(7):1472-1482. DOI: 10.1097/TP.0000000000003006. https://doi.org/10.1097/TP.0000000000003006
  18. Podestà MA, Binder C, Sellberg F, DeWolf S, Shonts B, Ho SH, Obradovic A, Waffarn E, Danzl N, Berglund D, Sykes M. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro. American Journal of Transplantation 2020;20(1):88-100. DOI: 10.1111/ajt.15533. https://doi.org/10.1111/ajt.15533
  19. Issa F, Strober S, Leventhal JR, Kawai T, Kaufman DB, Levitsky J, Sykes M, Mas V, Wood KJ, Bridges N, Welniak LA, Chandran S, Madsen JC, Nickerson P, Demetris AJ, Lakkis FG, Thomson AW. The Fourth International Workshop on Clinical Transplant Tolerance. American Journal of Transplantation 2021;21(1):21-31. DOI: 10.1111/ajt.16139. https://doi.org/10.1111/ajt.16139
  20. Kwon Y, Lee KW, Kim YM, Park H, Jung MK, Choi YJ, Son JK, Hong J, Park SH, Kwon GY, Yoo H, Kim K, Kim SJ, Park JB, Shin EC. Expansion of CD45RA−FOXP3++ regulatory T cells is associated with immune tolerance in patients with combined kidney and bone marrow transplantation. Clinical and Translational Immunology 2021;10(8):e1325. DOI: 10.1002/cti2.1325. https://doi.org/10.1002/cti2.1325
  21. Sasaki H, Hirose T, Oura T, Otsuka R, Rosales I, Ma D, Lassiter G, Karadagi A, Tomosugi T, Dehnadi A, Matsunami M, Raju Paul S, Reeves PM, Hanekamp I, Schwartz S, Colvin RB, Lee H, Spitzer TR, Cosimi AB, Cippà PE, Fehr T, Kawai T. Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates. Science Translational Medicine 2023;15(690):eadd5318. DOI: 10.1126/scitranslmed.add5318. https://doi.org/10.1126/scitranslmed.add5318
  22. Tonsho M, O JM, Ahrens K, Robinson K, Sommer W, Boskovic S, Patel PM, Becerra DC, Huh KH, Miller CL, Dehnadi A, Hanekamp I, Rosales IA, Colvin RB, Sachs DH, Alessandrini A, Cosimi A, Fairchild RL, Cravedi P, Bin S, Heeger PS, Allan JS, Kawai T, Benichou G, Madsen JC. Cardiac allograft tolerance can be achieved in nonhuman primates by donor bone marrow and kidney cotransplantation. Science Translational Medicine 2025;17(782):eads0255. DOI: 10.1126/scitranslmed.ads0255. https://doi.org/10.1126/scitranslmed.ads0255
  23. Wilson A, Souffrant A, Hansen B, Cosimi AB, Sachs DH, Kawai T. Preclinical and clinical studies on kidney allograft tolerance via hematopoietic chimerism. American Journal of Transplantation 2026;26(8):1775-1786. DOI: 10.1016/j.ajt.2026.03.011. https://doi.org/10.1016/j.ajt.2026.03.011